Your browser doesn't support javascript.
loading
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz, C; Castroviejo-Bermejo, M; Gutiérrez-Enríquez, S; Llop-Guevara, A; Ibrahim, Y H; Gris-Oliver, A; Bonache, S; Morancho, B; Bruna, A; Rueda, O M; Lai, Z; Polanska, U M; Jones, G N; Kristel, P; de Bustos, L; Guzman, M; Rodríguez, O; Grueso, J; Montalban, G; Caratú, G; Mancuso, F; Fasani, R; Jiménez, J; Howat, W J; Dougherty, B; Vivancos, A; Nuciforo, P; Serres-Créixams, X; Rubio, I T; Oaknin, A; Cadogan, E; Barrett, J C; Caldas, C; Baselga, J; Saura, C; Cortés, J; Arribas, J; Jonkers, J; Díez, O; O'Connor, M J; Balmaña, J; Serra, V.
Affiliation
  • Cruz C; Experimental Therapeutics Group; High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona.
  • Castroviejo-Bermejo M; Experimental Therapeutics Group.
  • Gutiérrez-Enríquez S; Oncogenetics Group.
  • Llop-Guevara A; Experimental Therapeutics Group.
  • Ibrahim YH; Experimental Therapeutics Group.
  • Gris-Oliver A; Experimental Therapeutics Group.
  • Bonache S; Oncogenetics Group.
  • Morancho B; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Bruna A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge.
  • Rueda OM; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge.
  • Lai Z; AstraZeneca, Gatehouse Park, Waltham, USA.
  • Polanska UM; DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Jones GN; DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Kristel P; Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Bustos L; Experimental Therapeutics Group.
  • Guzman M; Experimental Therapeutics Group.
  • Rodríguez O; Experimental Therapeutics Group.
  • Grueso J; Experimental Therapeutics Group.
  • Montalban G; Oncogenetics Group.
  • Caratú G; Cancer Genomics Group.
  • Mancuso F; Cancer Genomics Group.
  • Fasani R; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Jiménez J; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Howat WJ; DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Dougherty B; AstraZeneca, Gatehouse Park, Waltham, USA.
  • Vivancos A; Cancer Genomics Group.
  • Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Serres-Créixams X; Department of Radiology.
  • Rubio IT; Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona.
  • Oaknin A; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona; Gynecological Malignancies Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Cadogan E; DNA Damage Response Biology Area, Oncology iMed, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Barrett JC; AstraZeneca, Gatehouse Park, Waltham, USA.
  • Caldas C; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Ca
  • Baselga J; Human Oncology and Pathogenesis Program (HOPP); Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Saura C; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Cortés J; Ramón y Cajal University Hospital, Madrid; Vall d'Hebron Institute of Oncology, Barcelona.
  • Arribas J; Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Department of Biochemistry and Molecular Biology, Building M, Campus UAB, Bellaterra (Cerdanyola del Vallès); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; CIBERONC, Barcelona.
  • Jonkers J; Cancer Genomics Group.
  • Díez O; Oncogenetics Group; Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • O'Connor MJ; DNA Damage Response Biology Area, Oncology Innovative Medicine and Early Development Biotech Unit, AstraZeneca, Cambridge, UK.
  • Balmaña J; High Risk and Familial Cancer, Vall d'Hebron Institute of Oncology, Barcelona; Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona.
  • Serra V; Experimental Therapeutics Group; CIBERONC, Barcelona. Electronic address: vserra@vhio.net.
Ann Oncol ; 29(5): 1203-1210, 2018 05 01.
Article in En | MEDLINE | ID: mdl-29635390
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Biomarkers, Tumor / Drug Resistance, Neoplasm / Rad51 Recombinase / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Female / Humans Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Biomarkers, Tumor / Drug Resistance, Neoplasm / Rad51 Recombinase / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Female / Humans Language: En Year: 2018 Type: Article